 The initial intravenous administrations are followed up by orally prescribed medications and behavioral treatment.Preliminary evidence that a regimen combining hydroxyzine, flumazenil and gabapentin - i.e.the active pharmacological components of Prometa - can help decrease methamphetamine cravings and use was first published in October 2007 following a relatively small, open-label trial by Dr. Harold C. Urschel.